Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
Launched by EUGONIA · Dec 28, 2006
Trial Information
Current as of May 08, 2025
Completed
Keywords
ClinConnect Summary
Poor responders are women who fail to respond effectively to the usual gonadotropin stimulation protocol applied in an IVF cycle. It seems that a diminished ovarian reserve is the principal factor of poor ovarian response. Several strategies have been proposed for the management of poor responders, including flare up GnRH agonist regimens and the GnRH antagonist, which presents a new hope in this group of patients.
Comparisons: Poor responder patients (see inclusion criteria) commencing an IVF treatment cyle will receive ovarian stimulation treatment either using a GnRH antagonist (Ganirel...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • regular menstrual cycle
- • 1 or more failed IVF attempts with poor response
- • 5 or fewer oocytes retrieved
- • FSH\>12 IU/l on day 3
- Exclusion Criteria:
- • PCOS
- • Normal responders
About Eugonia
Eugonia is a pioneering clinical trial sponsor dedicated to advancing innovative therapeutic solutions in the field of regenerative medicine. With a commitment to enhancing patient outcomes, Eugonia specializes in the development and execution of cutting-edge clinical trials that focus on harnessing the body's natural healing processes. The organization is driven by a team of experienced professionals who prioritize scientific integrity, patient safety, and regulatory compliance. By fostering collaborations with leading research institutions and healthcare providers, Eugonia aims to accelerate the translation of groundbreaking research into effective treatments, ultimately improving the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Athens, , Greece
Patients applied
Trial Officials
Tryfon Lainas, PhD
Study Director
Eugonia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials